Clinical Trials in Progress for Urologic Cancers

Published: Tuesday, Aug 21, 2012
The Trials in Progress section is intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the urology community. In each issue, Urologists in Cancer Care will present summaries of ongoing research relating to a variety of urologic cancers.

Bladder Cancer

Intravesical EN3348 vs mitomycin C for bladder cancer

This phase III study will compare EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) with mitomycin C in the intravesical treatment of patients with bacillus Calmette-Guérin (BCG)-recurrent or -refractory nonmuscle invasive bladder cancer (Ta high grade, T1 low or high grade, or carcinoma in situ). Refractory disease in the roughly 450-patient study is defined as evidence of persistent high-grade bladder cancer (Ta HG, T1, and/or CIS) at least 6 months from the start of a full induction course of BCG with or without maintenance/retreatment at 3 months. Recurrent disease is defined as the reappearance of disease after achieving a tumor-free status by 6 months following a full induction course of BCG with or without maintenance/retreatment at 3 months; subjects with recurrent disease must have had their recurrence within 18 months following the last dose of BCG. The primary outcome measure is efficacy. About 450 patients will participate at 77 sites.

Sponsor: Endo Pharmaceuticals

ClinicalTrials.gov Identifier: NCT01200992


Prostate Cancer

Zoledronate for bone loss prevention in prostate cancer

This phase III trial study will compare the effectiveness of the bisphosphonate zoledronate combined with calcium versus calcium alone for preventing bone loss in men with stage III or IV prostate cancer who have received long-term androgen-deprivation therapy. Patients randomized to the experimental arm receive zoledronate administered intravenously over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily, with the regimen repeated every 3 months for 12 months in the absence of toxicity. Patients assigned to the active comparator arm receive oral calcium gluconate and oral cholecalciferol without zoledronate. The primary outcome measure is bone density change as measured by dual-energy x-ray absorptiometry from baseline to 13 months. The researchers will also determine the percentage change in lumbar spine and hip bone density as measured by plain film x-rays of lumbar spine and pelvis and assess markers of bone formation and resorption, the incidence of skeletal events, and the incidence of new or progressive bone metastatic disease.

Sponsor: Northwestern University

ClinicalTrials.gov Identifier: NCT00058188


Tadalafil for preventing post-radiotherapy erectile dysfunction in prostate cancer

This phase III study is testing the effectiveness of the phosphodiesterase 5 inhibitor tadalafil for preventing erectile dysfunction in men treated with radiotherapy for prostate cancer. Patients are stratified according to age (≤ 65 years vs > 65 years) and radiotherapy treatment (external-beam radiotherapy alone to the prostate ± seminal vesicles only at a dose of 75-79.2 Gy or brachytherapy alone). Afterwards, they are randomized to receive oral tadalafil or placebo once daily for 24 weeks in the absence of disease progression or unacceptable toxicity. The primary outcome measure is spontaneous (off-drug) erectile function as measured by the International Index of Erectile Function at weeks 28-30. The estimated primary completion date is April 2013.

Sponsor: Radiation Therapy Oncology Group

ClinicalTrials.gov Identifier: NCT00931528


Prechemotherapy tasquinimod for advanced prostate cancer

This phase III study will compare tasquinimod versus placebo in men with asymptomatic to mildly symptomatic metastatic castration-resistant prostate cancer prior to chemotherapy. Tasquinimod is a second-generation oral quinoline-3-carboxamide analogue. Approximately 1200 patients will be randomly assigned in a 2:1 ratio to treatment with tasquinimod 0.25, 0.5, or 1 mg daily, or placebo. The primary outcome measure is progression-free survival. Investigators at 219 sites are participating and hope to complete the study by January 2016. In order to be eligible, patients must have evidence of bone metastatic disease on radiographic examination and evidence of progressive disease after castration levels of testosterone have been achieved, and a Karnofsky score ≥70%.

Sponsor: Active Biotech AB

ClinicalTrials.gov Identifier: NCT01234311


Recombinant vaccine for metastatic prostate cancer


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field ForwardMay 30, 20181.5
Publication Bottom Border
Border Publication
x